Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.

Bhatia A, Birger M, Veeraraghavan H, Um H, Tixier F, Mckenney AS, Cugliari M, Caviasco A, Bialczak A, Malani R, Flynn J, Zhang Z, Yang TJ, Santomasso BD, Shoushtari AN, Young RJ.

Neuro Oncol. 2019 Oct 17. pii: noz141. doi: 10.1093/neuonc/noz141. [Epub ahead of print]

PMID:
31621883
2.

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.

Freeman M, Betts KA, Jiang S, Du EX, Gupte-Singh K, Lu Y, Rao S, Shoushtari AN.

Adv Ther. 2019 Oct;36(10):2783-2796. doi: 10.1007/s12325-019-01060-y. Epub 2019 Aug 22.

3.

About Face: Molecular Aberrations in Head and Neck Mucosal Melanomas.

Shoushtari AN.

Clin Cancer Res. 2019 Jun 15;25(12):3473-3475. doi: 10.1158/1078-0432.CCR-19-0658. Epub 2019 Apr 5.

PMID:
30952641
4.

Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.

Lee Chuy K, Oikonomou EK, Postow MA, Callahan MK, Chapman PB, Shoushtari AN, Neilan TG, Fradley MG, Ramanathan LV, Wolchok JD, Steingart RM, Gupta D.

Oncologist. 2019 May;24(5):e196-e197. doi: 10.1634/theoncologist.2019-0040. Epub 2019 Mar 25. No abstract available.

PMID:
30910868
5.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
6.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN.

Cancer. 2019 Mar 15;125(6):884-891. doi: 10.1002/cncr.31889. Epub 2018 Dec 6.

PMID:
30521084
7.

Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma.

Francis JH, Catalanotti F, Landa J, Barker CA, Shoushtari AN, Abramson DH.

Br J Ophthalmol. 2019 Sep;103(9):1266-1271. doi: 10.1136/bjophthalmol-2018-312612. Epub 2018 Oct 31.

PMID:
30381389
8.

A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.

Kelly CM, Shoushtari AN, Qin LX, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Mcfadyen C, Sjoberg A, Singer S, DeMatteo RP, Hwang S, Heinemann MH, Francis JH, Antonescu CR, Chi P, Tap WD.

Invest New Drugs. 2019 Apr;37(2):282-290. doi: 10.1007/s10637-018-0648-z. Epub 2018 Aug 13.

9.

Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma.

Gottesdiener LS, O'Connor S, Busam KJ, Won H, Solit DB, Hyman DM, Shoushtari AN.

Clin Cancer Res. 2018 Dec 1;24(23):5815-5819. doi: 10.1158/1078-0432.CCR-18-1397. Epub 2018 Aug 9.

10.

Primary and Metastatic Melanoma With NTRK Fusions.

Lezcano C, Shoushtari AN, Ariyan C, Hollmann TJ, Busam KJ.

Am J Surg Pathol. 2018 Aug;42(8):1052-1058. doi: 10.1097/PAS.0000000000001070.

11.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.

J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. Erratum in: J Clin Oncol. 2018 Dec 10;36(35):3528.

PMID:
29528792
12.

GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.

Moore AR, Ran L, Guan Y, Sher JJ, Hitchman TD, Zhang JQ, Hwang C, Walzak EG, Shoushtari AN, Monette S, Murali R, Wiesner T, Griewank KG, Chi P, Chen Y.

Cell Rep. 2018 Feb 27;22(9):2455-2468. doi: 10.1016/j.celrep.2018.01.081.

13.

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, Panageas KS, Postow MA.

Cancer Med. 2018 Mar;7(3):690-697. doi: 10.1002/cam4.1356. Epub 2018 Feb 22.

14.

Treatment of advanced melanoma - A changing landscape.

Hepner A, Salgues A, Anjos CAD, Sahade M, Camargo VP, Garicochea B, Shoushtari AN, Postow MA, Fernandes GS, Munhoz RR.

Rev Assoc Med Bras (1992). 2017 Sep;63(9):814-823. doi: 10.1590/1806-9282.63.09.814. Review.

15.

Association of Surgical Approach and Margin Status With Oncologic Outcomes Following Gross Total Resection for Sinonasal Melanoma.

Sayed Z, Migliacci JC, Cracchiolo JR, Barker CA, Lee NY, McBride SM, Tabar VS, Ganly I, Patel SG, Morris LT, Roman BR, Shoushtari AN, Cohen MA.

JAMA Otolaryngol Head Neck Surg. 2017 Dec 1;143(12):1220-1227. doi: 10.1001/jamaoto.2017.2011. No abstract available.

16.

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN.

Ann Oncol. 2018 Jan 1;29(1):250-255. doi: 10.1093/annonc/mdx642.

17.

OncoKB: A Precision Oncology Knowledge Base.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.

18.

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB.

JAMA Oncol. 2018 Jan 1;4(1):98-101. doi: 10.1001/jamaoncol.2017.2391.

19.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004c. No abstract available.

PMID:
28777785
20.

An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses.

Vasan N, Braghiroli MI, Shoushtari AN, Do RKG, Edelweiss M, Shamseddine A, Faraj W, Mukherji D, Haydar A, Olayan A, Sabatin F, Assi R, El Dika I, Saltz LB, Abou-Alfa GK, O'Reilly EM.

J Gastrointest Oncol. 2017 Jun;8(3):596-602. doi: 10.21037/jgo.2017.01.21. No abstract available.

21.

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F.

Ophthalmology. 2017 Dec;124(12):1788-1798. doi: 10.1016/j.ophtha.2017.05.038. Epub 2017 Jul 12.

22.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

23.

Patient perspectives on ipilimumab across the melanoma treatment trajectory.

Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, Roth KG, Flavin M, Granobles A, Christian J, Gold G, Schoenhammer M, Gordon M, Cimaglia N, Dyson R, Goodman-Davis N, Colgan MN, Jefferson IS, Munhoz R, D'Angelo S, Wolchok J, Chapman P, Chi P, Carvajal RD, Hay JL.

Support Care Cancer. 2017 Jul;25(7):2155-2167. doi: 10.1007/s00520-017-3621-z. Epub 2017 Mar 1.

24.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD.

J Clin Oncol. 2017 Jan 10;35(2):226-235. Epub 2016 Nov 7.

25.

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, Callahan MK, Wolchok JD, Chapman PB, Hellmann MD, Postow MA.

J Natl Cancer Inst. 2016 Dec 31;109(4). doi: 10.1093/jnci/djw260. Print 2017 Apr.

26.

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.

D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD.

Clin Cancer Res. 2017 Jun 15;23(12):2972-2980. doi: 10.1158/1078-0432.CCR-16-2349. Epub 2016 Dec 22.

27.

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, Chapman PB, Carvajal RD.

Melanoma Res. 2017 Feb;27(1):57-64. doi: 10.1097/CMR.0000000000000306.

28.

The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA.

Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17.

29.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ.

Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.

30.

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.

Ann Oncol. 2017 Feb 1;28(2):368-376. doi: 10.1093/annonc/mdw443.

PMID:
27687304
31.

Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract.

Schiavone MB, Broach V, Shoushtari AN, Carvajal RD, Alektiar K, Kollmeier MA, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol Rep. 2016 Apr 14;16:42-6. doi: 10.1016/j.gore.2016.04.001. eCollection 2016 Apr.

32.

Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma.

Shoushtari AN, Landa J, Kuk D, Sanchez A, Lala B, Schmidt N, Okoli C, Chi P, Dickson MA, Gounder MM, Keohan ML, Crago AM, Tap WD, D'Angelo SP.

Sarcoma. 2016;2016:3547497. doi: 10.1155/2016/3547497. Epub 2016 May 29.

33.

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA.

Oncologist. 2016 Jul;21(7):848-54. doi: 10.1634/theoncologist.2015-0522. Epub 2016 Jun 10.

34.

Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum.

Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko JM, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE.

Pigment Cell Melanoma Res. 2016 Jul;29(4):470-3. doi: 10.1111/pcmr.12482. No abstract available.

35.

Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.

Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, Zhang JQ, Walczak EG, Kazmi MA, Taylor BS, Huber T, Chi P, Sakmar TP, Chen Y.

Nat Genet. 2016 Jun;48(6):675-80. doi: 10.1038/ng.3549. Epub 2016 Apr 18.

36.

Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.

Samstein RM, Carvajal RD, Postow MA, Callahan MK, Shoushtari AN, Patel SG, Lee NY, Barker CA.

Head Neck. 2016 Sep;38(9):1310-7. doi: 10.1002/hed.24435. Epub 2016 Apr 4.

37.

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.

Shoushtari AN, Ong LT, Schoder H, Singh-Kandah S, Abbate KT, Postow MA, Callahan MK, Wolchok J, Chapman PB, Panageas KS, Schwartz GK, Carvajal RD.

Melanoma Res. 2016 Jun;26(3):272-7. doi: 10.1097/CMR.0000000000000234.

38.

Treatment of Uveal Melanoma.

Shoushtari AN, Carvajal RD.

Cancer Treat Res. 2016;167:281-93. doi: 10.1007/978-3-319-22539-5_12. Review.

PMID:
26601868
39.

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation.

Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD.

J Immunother Cancer. 2015 Jun 16;3:22. doi: 10.1186/s40425-015-0066-0. eCollection 2015.

40.

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.

D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD.

Hum Pathol. 2015 Mar;46(3):357-65. doi: 10.1016/j.humpath.2014.11.001. Epub 2014 Nov 15.

41.

GNAQ and GNA11 mutations in uveal melanoma.

Shoushtari AN, Carvajal RD.

Melanoma Res. 2014 Dec;24(6):525-34. doi: 10.1097/CMR.0000000000000121. Review.

PMID:
25304237
42.

Novel treatment targets in sarcoma: more than just the GIST.

Shoushtari AN, Van Tine BA, Schwartz GK.

Am Soc Clin Oncol Educ Book. 2014:e488-95. doi: 10.14694/EdBook_AM.2014.34.e488. Review.

43.

A woman with metastatic pancreatic neuroendocrine tumor.

Shoushtari AN, Covey AM, Zaatari G, Shamseddine A, Epstein AS, Haydar A, Naghy M, Mukherji D, Kelsen DP, Abou-Alfa GK, O'Reilly EM.

Gastrointest Cancer Res. 2014 Jan;7(1):27-32. No abstract available.

44.

Quantifying the reproducibility of heart position during treatment and corresponding delivered heart dose in voluntary deep inhalation breath hold for left breast cancer patients treated with external beam radiotherapy.

McIntosh A, Shoushtari AN, Benedict SH, Read PW, Wijesooriya K.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e569-76. doi: 10.1016/j.ijrobp.2011.01.044. Epub 2011 Apr 29.

PMID:
21531087
45.

Metastasis-suppressor genes in clinical practice: lost in translation?

Shoushtari AN, Szmulewitz RZ, Rinker-Schaeffer CW.

Nat Rev Clin Oncol. 2011 Jun;8(6):333-42. doi: 10.1038/nrclinonc.2011.65. Epub 2011 Apr 26. Review.

PMID:
21522123
46.

Primary nasopharyngeal interdigitating dendritic cell tumor presentation and response to radiation therapy.

Dunlap NE, Woodford RL, Shoushtari AN, Reibel JF, Douvas MG, Cousar JB, Read PW.

Rare Tumors. 2010 Mar 31;2(1):e9. doi: 10.4081/rt.2010.e9.

47.

Clinical nodal staging of T1-2 tonsillar squamous cell carcinoma stratified by p16 status and implications for ipsilateral neck irradiation.

Shoushtari AN, Meeneghan M, Treharne GC, Reibel JF, Levine PA, Moskaluk CA, Jameson MJ, Read PW.

Cancer J. 2010 May-Jun;16(3):284-7. doi: 10.1097/PPO.0b013e3181ddd088.

PMID:
20526108
48.

Survey on human papillomavirus/p16 screening use in oropharyngeal carcinoma patients in the United States.

Shoushtari AN, Rahimi NP, Schlesinger DJ, Read PW.

Cancer. 2010 Jan 15;116(2):514-9. doi: 10.1002/cncr.24752.

49.

Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status.

Shonka DC Jr, Shoushtari AN, Thomas CY, Moskaluk C, Read PW, Reibel JF, Levine PA, Jameson MJ.

Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1126-32. doi: 10.1001/archoto.2009.153.

PMID:
19917926
50.

Calculation and prediction of the effect of respiratory motion on whole breast radiation therapy dose distributions.

Cao J, Roeske JC, Chmura SJ, Salama JK, Shoushtari AN, Boyer AL, Martel MK.

Med Dosim. 2009 Summer;34(2):126-32. doi: 10.1016/j.meddos.2008.07.002. Epub 2008 Sep 4.

PMID:
19410141

Supplemental Content

Loading ...
Support Center